Active, not recruitingPhase 3NCT05734105
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Studying Gastrointestinal stromal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Principal Investigator
- Clinical TeamDeciphera Pharmaceuticals, LLC
- Intervention
- Ripretinib(drug)
- Enrollment
- 54 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Yale University, New Haven, Connecticut, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Boston Medical Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Northwell Health Cancer Institute/ R.J. Zuckerberg Cancer Center, New York, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05734105 on ClinicalTrials.govOther trials for Gastrointestinal stromal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego
- RECRUITINGNANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPHASE1NCT06655246A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Kura Oncology, Inc.
- RECRUITINGNANCT06926374Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic SurgeryChinese University of Hong Kong
- RECRUITINGNANCT07411118RCT of EFTR Versus STER for GIST TreatmentChinese University of Hong Kong
- RECRUITINGPHASE1, PHASE2NCT06630234A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)Deciphera Pharmaceuticals, LLC
- RECRUITINGPHASE3NCT06640361A Study of Olverembatinib in SDH-deficient GIST.Ascentage Pharma Group Inc.